Table 1 Baseline characteristics data of patients and healthy donors
From: Pretreatment of UC-MSCs with IFN-α2 improves treatment of liver fibrosis by recruiting neutrophils
Factors | Liver cirrhosis (n = 30) | Healthy donors (n = 10) | P value |
|---|---|---|---|
Age (years) | |||
Medium | 48 | 46 | |
Range | 26–68 | 24–72 | 0.69 |
Sex (M/F) | 18/12 | 5/5 | 0.72 |
AST (U/L) | 22.3 ± 5.61 | 63.5 ± 57.25 | 0.001 |
ALT (U/L) | 15.9 ± 6.99 | 47.8 ± 42.80 | 0.001 |
ALB (g/L) | 43.1 ± 4.21 | 38.6 ± 7.46 | 0.03 |
TBiL (µmol/L) | 13.9 ± 5.81 | 45.8 ± 63.12 | 0.01 |
Serum IFN-α2 (pg/mL) | 7.4 ± 0.41 | 55.6 ± 57.43 | < 0.001 |